Clinical Trials on Plexiform Neurofibroma in China

Total 16 results

AstraZeneca
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)

Neurofibromatosis 1 | Neurofibroma Plexiform

China
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

A Retrospective Study on Epidemiological Characteristics of Chinese NF1 Patients in Real World (PROMISE)

Neurofibromatosis 1 | Plexiform Neurofibroma

China
Shanghai Fosun Pharmaceutical Industrial Development...

Recruiting

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas

Neurofibromatosis 1 | NF1 | Plexiform Neurofibroma

China
AstraZeneca
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas (KOMET)

Neurofibromatosis 1 | Plexiform Neurofibroma (PN)

United States, Canada, France, Italy, Germany, China, United Kingdom, Spain, Japan, Russian Federation, Australia, Poland, Brazil
Shanghai Kechow Pharma, Inc.

Recruiting

HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Neurofibromatosis 1 | Plexiform Neurofibromas

China
Shanghai Fosun Pharmaceutical Industrial Development...

Active, not recruiting

Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1

Neurofibromatosis 1 | NF1 | Plexiform Neurofibroma

United States, China, Spain
AstraZeneca

Withdrawn

Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled Study (PROTECT)

Neurofibromatosis Type 1 | Plexiform Neurofibromas | Post-operative

China
AstraZeneca

Recruiting

Observational Study to Evaluate the Effect and Safety of Selumetinib in Pediatric Patients With NF1-PNs (PEDIA)

Neurofibroma, Plexiform

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of TQ-B3234 in Patients With Type I Neurofibromatosis

Type I Neurofibromatosis

China
Shenzhen Geno-Immune Medical Institute
Shenzhen Children's Hospital; Shenzhen Hospital of Southern Medical University

Unknown

Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis

Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Terminated

A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis

Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors

China
Li Peng
Betta Pharmaceuticals Co., Ltd.

Completed

Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors (Icotinib)

Neurofibromatosis Type 2 | Vestibular Schwannoma

China
Beijing Tiantan Hospital
Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd

Completed

Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors (Endostatin)

Neurofibromatosis Type 2 | Vestibular Schwannoma

China
HRYZ Biotech Co.

Not yet recruiting

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

Leiomyosarcoma | Fibrosarcoma | Liposarcoma | Angiosarcoma | Synovial Sarcoma | Endometrial Stromal Sarcoma | Undifferentiated Pleomorphic Sarcoma | Epithelioid Sarcoma | Desmoplastic Small Round Cell Tumor | Malignant Peripheral Nerve Sheath Tumors | Pleomorphic Rhabdomyosarcoma

China
National Cancer Institute (NCI)

Terminated

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

High Grade Sarcoma | Metastatic Leiomyosarcoma | Stage III Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IV Uterine Corpus Leiomyosarcoma AJCC v8 | Unresectable Leiomyosarcoma | Myxofibrosarcoma | Metastatic Malignant Peripheral Nerve Sheath Tumor | Metastatic Synovial Sarcoma | Metastatic Undifferentiated... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Malignant Solid Neoplasm | Nasopharyngeal Carcinoma | Adenoid Cystic Carcinoma | Transitional Cell Carcinoma | Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | Chordoma | Gestational Trophoblastic Tumor | Pseudomyxoma Peritonei | Cervical Adenocarcinoma | Vaginal Adenocarcinoma | Vaginal Squamous Cell... and other conditions

United States, Guam

Clinical Trials on Plexiform Neurofibroma in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations